News

Osborne Clarke advises Grifols on strategic USD 1 billion investment from GIC


Written on 30 June 2021

International legal practice Osborne Clarke has advised global healthcare leader, Grifols on a ~USD 1 billion strategic investment from Singapore’s sovereign wealth fund.

As part of the transaction, GIC will become a strategic investor in Grifols’ business, holding a minority stake in Biomat USA through the acquisition of newly issued non-voting stock.

Biomat is a global leader in plasma collection, with a network of 296 U.S.-based plasma collection centers. Grifols will continue to oversee all aspects of Biomat’s management and operations. All plasma collected by Biomat and its subsidiaries will continue to be supplied to Grifols for the production of plasma-derived medicines, through a long-term plasma supply agreement.

Grifols’ leadership in the manufacture of plasma-based medicines, extensive expertise in the expansion and management of plasma centers, market know-how, and outstanding reputation were all key factors in GIC’s decision to invest in the company.

The team that advised on the matter was led by corporate partner Tomás Dagá who was assisted by Partner Oscar Calsamiglia and Laura de la Cruz.

Osborne Clarke’s Corporate team is considered the go-to practice for many businesses in the life sciences and healthcare sector. The team advises at every stage of company development across all corporate areas, from equity and debt fundraising to M&A, IPOs and JVs.

Grifols was also advised by Proskauer Rose on US Law and its financial advisor was Nomura Securities International. GIC retained Dechert LLP as legal advisor.